Intelgenx Technologies (Intelgenx Technologies) DeferredTaxAndRevenue

: $1.12 Mil (As of Dec. 2023)

View and export this data going back to 2006. Start your Free Trial

Deferred Tax And Revenue represents the current portion of obligations, which is a liability that usually would have been paid but is now pas due.

Intelgenx Technologies's current deferred tax and revenue for the quarter that ended in Dec. 2023 was $1.12 Mil.

Intelgenx Technologies DeferredTaxAndRevenue Historical Data

The historical data trend for Intelgenx Technologies's DeferredTaxAndRevenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Intelgenx Technologies Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

DeferredTaxAndRevenue

0.17

0.19

1.12

Intelgenx Technologies Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
DeferredTaxAndRevenue																-	-	-	0.29	1.12

Intelgenx Technologies DeferredTaxAndRevenue Related Terms

Thank you for viewing the detailed overview of Intelgenx Technologies's DeferredTaxAndRevenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Intelgenx Technologies (Intelgenx Technologies) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Intelgenx Technologies Corp (OTCPK:IGXT) » Definitions » DeferredTaxAndRevenue

Comparable Companies

Traded in Other Exchanges

0IL:Germany IGX:Canada

Address

6420 Abrams, Ville Saint Laurent, QC, CAN, H4S 1Y2

Website

https://www.intelgenx.com

Intelgenx Technologies Corp is an oral drug delivery company. The company is focused on the development and manufacturing of pharmaceutical oral films based on its proprietary VersaFilmTM technology platform. Intelegenx focuses on the development of novel oral immediate-release and controlled-release products for the pharmaceutical market. It offers a comprehensive portfolio of pharmaceutical services, including pharmaceutical R&D, clinical monitoring, regulatory support, tech transfer and manufacturing scale-up, and commercial manufacturing. Its geographical segments are Europe, Canada, and United States.

Executives

Atai Life Sciences Ag	10 percent owner	KRAUSENSTRASSE 9-10, BERLIN 2M 10117
Atai Life Sciences N.v.	10 percent owner	524 BROADWAY, NEW YORK NY 10013
Karen Kalayajian	officer: VP, Finance&Admin - Subsidiary	4896 RUE EDOUARD-BRUNETTE, LAVAL A8 H7T 0J4
Dwight Gorham	officer: CEO	15B BARKLEY ST, ARNPRIOR A6 K7S 3G8
David Kideckel	officer: SVP, Corp. Dev&SA - Subsidiary	23 PEVERIL HILL SOUTH, TORONTO, ON A6 M6C 3A7
Horst G Zerbe	10 percent owner, officer: Chief Executive Officer	714 MAIN ROAD, HUDSON A8 JOP1H0
Andre Godin	officer: CFO	440 DES CARMANTINES, LAVAL A8 H7X 0B6
Tommy Kenny	officer: VP IP,Lgl Affairs - Subsidiary	88 CH. DES SAULES, ST-ADOLPHE D' HOWARD A8 J0T 2B0
Dana Matzen	officer: VP Business+Corp. Development	4771 RUE SHERBROOKE O., WESTMOUNT A8 H3Z1G5
Ingrid Zerbe	10 percent owner, officer: Corporate Secretary	714 MAIN ROAD, HUDSON A8 J0P1H0
Rodolphe Obeid	officer: Vice President, Operations	4779 RUE VILLERET, PIERREFOND A8 H9K1P6
Bernard Boudreau	director	2 TURNMILL DR., HALIFAX A5 B3M4H2
John Edward Durham	officer: Vice President Manufacturing	102 MAYFAIR, HUDSON A8 J0P1H0
Mark Nawacki	director	118 ARLINGTON AVENUE, WESTMOUNT A8 H3Y2W4
Robert J. Bechard	officer: VP Corporate Development	141 EASTON AVENUE, MONTREAL WEST A8 H4X 1L4